PDF(Pubmed)
Abstract：
Patients with haemophilia present a significant challenge when admitted into the intensive care unit. To prevent haemorrhagic complications related to the infection or due to invasive procedures factor (F) VIII/IX must be substituted. As thromboembolic complications are frequent among critically ill COVID-19 patients, thromboprophylaxis is also applied to patients with haemophilia. This requires careful monitoring of FVIII/IX activity as well as other haemostatic parameters, such as D-dimer and antiXa. We describe a 44-year old patient with mild haemophilia A (FVIII activity of 6%), who required a prolonged intensive care unit stay due to a severe SARS-CoV-2 infection. FVIII was substituted via boluses, and dalteparin was given according to recommendations. The patient successfully recovered from the disease.
摘要：
血友病患者进入重症监护病房时面临重大挑战。为了防止与感染相关或由于侵入性程序引起的出血并发症，必须替换（F）VIII/IX因子。由于血栓栓塞并发症在重症COVID-19患者中常见，血栓预防也适用于血友病患者。这需要仔细监测FVIII/IX活性以及其他止血参数，如D-二聚体和antiXa。我们描述了一名44岁的轻度A型血友病患者（FVIII活性为6％），由于严重的SARS-CoV-2感染而需要长时间的重症监护病房。FVIII通过丸剂取代，并根据建议给予达肝素。病人从疾病中成功康复。
